The majority reported using GLP-1 enhancers for weight reduction (319, 80.4%) and glucose control (212, 53.3%), while fewer used them for reducing the risks of obesity related disease (117, 29.4%). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.